Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series

被引:58
作者
Cusumano, Jaclyn A. [1 ,2 ,7 ]
Dupper, Amy C. [3 ,4 ]
Malik, Yesha [3 ,4 ]
Gavioli, Elizabeth M. [2 ,5 ]
Banga, Jaspreet [3 ]
Caban, Ana Berbel [4 ]
Nadkarni, Devika [3 ]
Obla, Ajay [6 ]
Vasa, Chirag V. [1 ]
Mazo, Dana [1 ,3 ,4 ]
Altman, Deena R. [4 ,6 ]
机构
[1] Mt Sinai Queens, Queens, NY USA
[2] Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Mt Sinai Hosp, Dept Med, Div Infect Dis, New York, NY USA
[5] Mt Sinai Beth Israel, New York, NY USA
[6] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA
[7] Arnold & Marie Schwartz Coll Pharm & Hlth Sci, 1 Univ Plaza, Brooklyn, NY 11201 USA
关键词
bacteremia; COVID-19; SARS-CoV-2; Staphylococcus aureus; ANTIRETROVIRAL-NAIVE ADULTS; ONCE-DAILY DOLUTEGRAVIR; NON-INFERIORITY; DOUBLE-BLIND; OPEN-LABEL; COFORMULATED ELVITEGRAVIR; TENOFOVIR ALAFENAMIDE; INITIAL TREATMENT; PHASE; 3B; HIV;
D O I
10.1093/ofid/ofaa518
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Previous viral pandemics have shown that secondary bacterial infections result in higher morbidity and mortality, with Staphylococcus aureus being the primary causative pathogen. The impact of secondary S. aureus bacteremia on mortality in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unknown.Methods This was a retrospective observational case series of patients with coronavirus disease 2019 (COVID-19) who developed secondary S. aureus bacteremia across 2 New York City hospitals. The primary end point was to describe 14-day and 30-day hospital mortality rates of patients with COVID-19 and S. aureus bacteremia. Secondary end points included predictors of 14-day and 30-day hospital mortality in patients with COVID-19 and S. aureus bacteremia.Results A total of 42 patients hospitalized for COVID-19 with secondary S. aureus bacteremia were identified. Of these patients, 23 (54.8%) and 28 (66.7%) died at 14 days and 30 days, respectively, from their first positive blood culture. Multivariate analysis identified hospital-onset bacteremia (>= 4 days from date of admission) and age as significant predictors of 14-day hospital mortality and Pitt bacteremia score as a significant predictor of 30-day hospital mortality (odds ratio [OR], 11.9; 95% CI, 2.03-114.7; P = .01; OR, 1.10; 95% CI, 1.03-1.20; P = .02; and OR, 1.56; 95% CI, 1.19-2.18; P = .003, respectively).Conclusions Bacteremia with S. aureus is associated with high mortality rates in patients hospitalized with COVID-19. Further investigation is warranted to understand the impact of COVID-19 and secondary S. aureus bacteremia.
引用
收藏
页数:7
相关论文
共 37 条
[1]   Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies [J].
Aboud, Michael ;
Orkin, Chloe ;
Podzamczer, Daniel ;
Bogner, Johannes R. ;
Baker, David ;
Khuong-Josses, Marie-Aude ;
Parks, David ;
Angelis, Konstantinos ;
Kahl, Lesley P. ;
Blair, Elizabeth A. ;
Adkison, Kimberly ;
Underwood, Mark ;
Matthews, Jessica E. ;
Wynne, Brian ;
Vandermeulen, Kati ;
Gartland, Martin ;
Smith, Kimberly .
LANCET HIV, 2019, 6 (09) :E576-E587
[2]   Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial [J].
Aboud, Michael ;
Kaplan, Richard ;
Lombaard, Johannes ;
Zhang, Fujie ;
Hidalgo, Jose A. ;
Mamedova, Elmira ;
Losso, Marcelo H. ;
Chetchotisakd, Ploenchan ;
Brites, Carlos ;
Sievers, Jorg ;
Brown, Dannae ;
Hopking, Judy ;
Underwood, Mark ;
Nascimento, Maria Claudia ;
Punekar, Yogesh ;
Gartland, Martin ;
Smith, Kimberly .
LANCET INFECTIOUS DISEASES, 2019, 19 (03) :253-264
[3]   Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial [J].
Arribas, Jose R. ;
Pialoux, Gilles ;
Gathe, Joseph ;
Di Perri, Giovanni ;
Reynes, Jacques ;
Tebas, Pablo ;
Thai Nguyen ;
Ebrahimi, Ramin ;
White, Kirsten ;
Piontkowsky, David .
LANCET INFECTIOUS DISEASES, 2014, 14 (07) :581-589
[4]   Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study [J].
Baldin, G. ;
Ciccullo, A. ;
Capetti, A. ;
Rusconi, S. ;
Sterrantino, G. ;
Cossu, M. V. ;
Giacomelli, A. ;
Lagi, F. ;
Latini, A. ;
Bagella, P. ;
De Luca, A. ;
Di Giambenedetto, S. ;
Madeddu, G. .
HIV MEDICINE, 2019, 20 (02) :164-168
[5]   Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study [J].
Cahn, Pedro ;
Pozniak, Anton L. ;
Mingrone, Horacio ;
Shuldyakov, Andrey ;
Brites, Carlos ;
Andrade-Villanueva, Jaime F. ;
Richmond, Gary ;
Beltran Buendia, Carlos ;
Fourie, Jan ;
Ramgopal, Moti ;
Hagins, Debbie ;
Felizarta, Franco ;
Madruga, Jose ;
Reuter, Tania ;
Newman, Tamara ;
Small, Catherine B. ;
Lombaard, John ;
Grinsztejn, Beatriz ;
Dorey, David ;
Underwood, Mark ;
Griffith, Sandy ;
Min, Sherene .
LANCET, 2013, 382 (9893) :700-708
[6]   Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study [J].
Castagna, Antonella ;
Maggiolo, Franco ;
Penco, Giovanni ;
Wright, David ;
Mills, Anthony ;
Grossberg, Robert ;
Molina, Jean-Michel ;
Chas, Julie ;
Durant, Jacques ;
Moreno, Santiago ;
Doroana, Manuela ;
Ait-Khaled, Mounir ;
Huang, Jenny ;
Min, Sherene ;
Song, Ivy ;
Vavro, Cindy ;
Nichols, Garrett ;
Yeo, Jane M. .
JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (03) :354-362
[7]   Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients [J].
Chen, Guan-Jhou ;
Sun, Hsin-Yun ;
Chang, Sui-Yuan ;
Cheng, Aristine ;
Huang, Yu-Shan ;
Lin, Kuan-Yin ;
Huang, Yi-Chia ;
Su, Yi-Ching ;
Liu, Wen-Chun ;
Hung, Chien-Ching .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (01) :35-42
[8]   Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study [J].
Clotet, Bonaventura ;
Feinberg, Judith ;
van Lunzen, Jan ;
Khuong-Josses, Marie-Aude ;
Antinori, Andrea ;
Dumitru, Irina ;
Pokrovskiy, Vadim ;
Fehr, Jan ;
Ortiz, Roberto ;
Saag, Michael ;
Harris, Julia ;
Brennan, Clare ;
Fujiwara, Tamio ;
Min, Sherene .
LANCET, 2014, 383 (9936) :2222-2231
[9]  
eacsociety.org, EACS Guidelines version 10.0
[10]  
Emberson JR, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029849, 10.1016/S0140-6736(12)60367-5]